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The second Herbert Fleisch Workshop was held in the beautiful city of Brugge, 1 
Belgium on February 28 to March 1, 2016. After the success of the first workshop, held 2 
also in Brugge in 2014, the IBMS board decided to support the repeat event as one 3 
which could be of great benefit to young investigators – PhD students, early 4 
postdoctoral researchers and early faculty members. This target audience was 5 
effectively reached, with 53% of the participants being younger than 35, and even up to 6 
84% being below 45 years of age.  7 
 8 
The same model of organization was pursued, with six senior investigators (“mentors”) 9 
being invited, each to give an in-depth review of their area of research in basic, applied 10 
and clinical and translational bone biology. This was with the aim of education of 11 
course, but also of inspiring the young participants in their work. A further task of the 12 
mentors was to engage fully with the participants throughout the meeting, discussing 13 
their poster and oral presentations and career directions. The mentors carried out these 14 
various functions assiduously, and their undivided attention throughout the several days 15 
of the meeting was very greatly appreciated by the participants.  16 
The meeting program was further build and driven by the young investigators attendees 17 
presenting their ongoing work. Posters were available for discussion at all times 18 
throughout the meeting and in the evenings, an aspect that was greatly appreciated. In 19 
addition to presenting their posters, as many as 34 of the participants were invited to 20 
give oral presentations. In these ways, the meeting design allowed those submitting 21 
abstracts maximum exposure and many possibilities for in-depth discussion of their 22 
work.  23 
A new feature that was added to this second edition of the meeting was the presentation 24 
of three methodological interactive workshops by some of the mentors. In her workshop 25 
on “Getting mouse phenotypes right”, Natalie Sims (Melbourne) discussed the 26 
essentials and the pitfalls that can be encountered in evaluating skeletal phenotypes in 27 
mice. Matt Warman (Boston) conducted a workshop on “gene editing using 28 
CRISPR/Cas9 technology”, pointing the participants to current resources and websites 29 
available in this new and rapidly advancing field, which is anticipated to be as 30 
revolutionary as polymerase chain reaction has proven to be. The workshop by Claire 31 
Edwards (Oxford) on “Mouse models of bone invasion by cancer” took participants 32 
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through the advantages and limitations of the in vivo approaches to studying how solid 1 
and hematological malignancies make their way in the bone microenvironment. These 2 
three workshops were so popular that the faculty members undertook generously to 3 
conduct each workshop twice, to increase exposure. They were very enthusiastically 4 
appreciated by all. 5 
 6 
 7 
The Magical, Multifunctional Osteocyte 8 
 9 
The opening session of the workshop focused on the osteocyte, a cell revealed as a most 10 
remarkable center of control in bone. Osteocytes comprise virtually 95% of all bone 11 
cells, and function to control the response of bone to mechanical loading, as well as 12 
regulating the levels of calcium and phosphorus, and finally by acting as an endocrine 13 
organ, affecting kidney, and possibly also muscle. The remarkable properties of 14 
osteocytes were discussed in the opening lecture by Lynda Bonewald (University of 15 
Missouri, Kansas City, USA), who pointed out that they are the longest lived of the 16 
cells of bone, crucial in sensing and then mediating the skeletal response to loading, as 17 
with deficiency of osteocytes  - e.g. too many empty lacunae – the response to loading 18 
is lost (1).  She also demonstrated that with ageing there is a profound loss of 19 
connectivity between osteocytes. 20 
 21 
One aspect of osteocyte function received special attention in the lecture was the control 22 
of the perilacunar matrix, an important source of calcium. Nanoindentation has 23 
identified a hypomineralised area within 5 µm of the osteocyte lacunae and the 24 
perilacunar space appears to have a low pH suggesting osteocytes may actively acidify 25 
this space. Osteocytes have been shown to express genes that are necessary for bone 26 
resorption, including TRAP, cathepsin K, v-ATPase and carbonic anhydrase I, and 27 
lacunar size was found to be increased during lactation in mice (2). Interestingly, such 28 
an increase was not found in mice in which the PTH receptor (PTHR1) was knocked out 29 
specifically in osteocytes, indicating that lactation-induced perilacunar resorption 30 
represents a PTHR1 signaling effect. 31 
 32 
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The location of osteocytes embedded deeply in bone has made them naturally very 1 
difficult to study, but progress was reported with the MLO-Y4 cell line and a new cell 2 
culture model, IDG-SW3 cells. These latter cells seem to recapitulate the differentiation 3 
process of osteoblasts into osteocytes, showing increased expression of osteocyte 4 
marker genes over several days in culture, and increased expression of PTHR1. In vitro 5 
experiments using these cell models suggest that osteocytes might also target muscle 6 
(3). Some early data presented at the meeting indicated that culture media from the 7 
MLO-Y4 cell line contained activities that could either enhance or inhibit myocyte 8 
differentiation of the C2C12 myoblast cell line, with this communication between 9 
osteocytes and muscle cells being strongly affected by age. Recent work had also shown 10 
in vivo that osteocytes produce factors that contribute to the age-related loss of muscle 11 
mass and function, as conditional deletion of the protease Mbtps1 in osteocytes led to 12 
an age-related muscle phenotype (4).  There is however one caveat here as it may well 13 
be that the DMP1-Cre is also expressed in muscle. 14 
Lynda Bonewald also discussed some of the roles of osteocytes as regulators of 15 
phosphate homeostasis and as endocrine cells regulating kidney through their 16 
production of FGF23, a topic further elaborated on by Seiji Fukumoto (Tokushima 17 
University, Tokushima, Japan) (see below).  18 
 19 
 20 
Indeed, osteocytes and their functions featured prominently in several of the 21 
presentations, both keynote lectures and short orals. Osteocyte biology was also the 22 
subject of a plenary presentation by Natalie Sims (St. Vincent’s Institute of Medical 23 
Research, Melbourne, Australia), who described striking and different effects in bone 24 
of disruption of three different signaling pathways.  25 
First, the actions of gp130 cytokines on the osteocyte had been indicated by the fact that 26 
oncostatin M and other members of the gp130 family rapidly decreased sclerostin 27 
production by osteocytes, in much the same way as did PTH and PTHrP. Investigating 28 
this further by osteocyte-specific knockout of gp130 revealed that gp130 was needed for 29 
normal bone formation and the anabolic response to PTH, and particularly was needed 30 
for normal lamellar bone formation (5, 6). 31 
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A second important pathway identified was ephrinB2 signaling. Having found that 1 
ephrinB2 production is rapidly increased by PTH and PTHrP in vitro and in vivo, mice 2 
rendered null (Osx-Cre) for the ephrinB2 gene exhibited a block in mid-differentiation, 3 
with a substantial increase in apoptosis of osteoblasts, increased mineralization lag-time 4 
and impairment of the PTH anabolic response (7-9). With knockout of ephrinB2 in the 5 
osteocyte however, there was no impairment of bone formation but a delay in 6 
mineralization, which was shown to be due to the fact that ephrinB2 is needed to 7 
maintain collagen structure and mineralization (10).  8 
The third pathway of interest was revealed through osteocyte-specific knockout of 9 
suppressor of cytokine signalling-3 (SOCS3). SOCS3 is an intracellular, ubiquitous, 10 
cytokine-inducible negative regulator of cytokine signaling, which functions to limit the 11 
action of gp130 cytokines in a negative feedback mechanism suppressing the JAK-12 
STAT signaling pathway. The DMP1-Cre-driven SOCS3 knockout mice were found to 13 
have poor corticalisation of bone, an effect that presented in a sex-divergent way with 14 
much more marked findings in female mice. Estrogen treatment of either 15 
orchidectomised males or ovariectomised females recapitulated the phenotype, 16 
suggesting an estrogen-dependent inhibition of the corticalization process resulted in 17 
marked improvement of cortex formation (11). 18 
 19 
These three signal pathways having different outcomes in earlier osteoblasts than in 20 
osteocytes (gp130 and ephrinB2) illustrated several aspects of osteocyte function, 21 
including a role for the osteocyte in the regulation of bone mass and collagen 22 
orientation, bone composition and mineralization, and organization of the trabecular and 23 
cortical compartments. Moreover, interesting physiological questions arise from the 24 
magnitude of the osteocyte network. Mathematical approaches have been used to 25 
estimate the size of the enormous network that comprises the osteocyte connections, 26 
with an analogy made between osteocytes and neurons (12). There are estimated to be 27 
42 billion osteocytes – compared to 86 billion neurons – with 175,000 kilometres of 28 
osteocyte processes and 150-180,000 kilometres of dendrites. Clearly, the osteocyte 29 
network is a highly complex communication network, of the same order of magnitude 30 
as current estimates of the neural network in the brain, adding perspective to the many 31 
local and endocrine functions of the osteocytes (12). 32 
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 1 
The osteocyte came up frequently for discussion throughout the meeting in varying 2 
contexts, and some of the short presentations had the osteocyte as a focus. Scott Youlten 3 
(Sydney) prepared bone marrow-deprived long bones and calvaria from mice to 4 
undertake transcriptome sequencing, identifying a 1126-gene osteocyte signature, which 5 
included the expected osteocyte genes as well as 73 long non-coding RNAs that were 6 
actively expressed in every replicate of each bone type. Many genes had not previously 7 
been annotated with osteocyte biology. While 87% of the osteocyte genes were found to 8 
be expressed in all bones examined, a small group of related transcription factors 9 
(mostly Hox-family genes) could delineate certain bones, for instance by a restricted 10 
expression in hind limb bones. The data from this work will provide a useful resource. 11 
Niloufar Ansari (Melbourne) reported on the phenotype of mice in which PTHrP was 12 
knocked out in the osteocyte, with the outcome indicating that osteocyte-derived PTHrP 13 
is required to maintain trabecular bone mass and the material strength of adult bones. 14 
She also reported findings with production and knockdown of PTHrP in the OCY454 15 
osteocyte cell line, to show that PTHrP acts as an autocrine and paracrine factor. If that 16 
is indeed the case in osteocytes in vivo, it could perhaps explain the PTHR1-dependent 17 
increase in perilacunar size described by Lynda Bonewald.  18 
 19 
 20 
Kidney-Bone Communication 21 
 22 
Another major function of the osteocyte is to act as an endocrine organ, as has been 23 
increasingly realized over the last several years. This is especially through production of 24 
FGF23, a phosphotrophic hormone, as discussed in detail by keynote speaker Seiji 25 
Fukumoto (Tokushima University, Tokushima, Japan). He outlined the several ways 26 
in which FGF23 decreased circulating levels of phosphate. It acts on the kidney to 27 
decrease NaPi IIa and IIc to decrease tubular reabsorption of phosphate, and to decrease 28 
formation of 1,25-dihydroxyvitamin D, with both mechanisms contributing to the low 29 
circulating levels of phosphate. 30 
 31 
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Abnormalities of FGF23 structure, metabolism or secretion are associated with a 1 
number of disorders, particularly X-linked hypophosphatemic rickets (XLHR) and 2 
tumour-induced osteomalacia (TIO). In the former condition, in a mouse model, an 3 
antibody against FGF23 corrects the disturbed phosphate levels, improves the skeleton, 4 
and corrects the disorganized growth plate (13). Efficacy has been shown in a clinical 5 
study of 28 patients with XLHR (14). The higher the levels of circulating FGF23 in 6 
chronic kidney disease (CKD), the higher the mortality (15, 16). A humanized 7 
monoclonal antibody is effective in TIO (17, 18). Anti-FGF23 is also effective in early 8 
CKD in rats in increasing 1,25-dihydroxyvitamin D and decreasing serum phosphate 9 
and PTH levels, but is ineffective in late stage CKD (19). 10 
Some of the interesting unresolved questions with FGF23 were discussed: (1) how does 11 
it work in the kidney, with its co-receptor Klotho expressed in the distal convoluted 12 
tubule, but the action on phosphate in the proximal tubule? (2) what triggers the 13 
increase in FGF23 in early CKD, and  (3) why is FGF23 associated with certain adverse 14 
events, for example cardiovascular effects, fractures, and mortality in kidney disease? 15 
 16 
There was much interest in this area also among the short communications. Despina 17 
Sitara (New York) had recently reported that genetic inactivation of FGF23 in mice 18 
resulted in increased hematopoietic stem cell frequency and red blood cell production, 19 
and inversely, infusion of FGF23 in wild-type mice reduced erythropoiesis (20). Having 20 
shown that FGF23 decreases erythropoiesis, she now used a mouse model of CKD (5/6-21 
nephrectomy) to show that the increased FGF23 was associated with reduced 22 
erythropoietin (EPO) levels and erythroid cells, which could be restored by 23 
administration of an FGF23 blocking peptide. Inhibition of FGF23 in this CKD model 24 
was found to decrease apoptosis of erythroid cells, improve erythropoiesis, and rescue 25 
anemia. Nina Bon (Nantes) studied the mechanism of the phosphaturic effect of FGF23, 26 
looking at the high affinity low capacity phosphate transporters, PiT1 and PiT2, 27 
producing evidence for a role of both in the phosphate sensing mechanisms in the 28 
kidney. An interesting aspect of FGF23 regulation was reported by Yuichi Takashi 29 
(Tokushima). It was known that O-glycosylation of FGF23 prevents the cleavage of 30 
FGF23 to inactive fragments, an effect that is prevented by GalNac-T3, a product of the 31 
GALNT3 gene. He showed that overexpression of GANLT3 in vitro increased the 32 
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release of active FGF23. Most interesting though, a high phosphate diet in mice 1 
increased GALNT3 expression in bone, as well as increasing circulating FGF23. A role 2 
for extracellular phosphate levels in post-translational processing of FGF23 would have 3 
important implications in CKD. 4 
 5 
 6 
Energy Metabolism of Bone Cells 7 
 8 
Each of the plenary speakers had new insights to offer as well as review material 9 
relevant to their work. In the case of Fanxin Long (Washington University, St. Louis, 10 
USA), we were taken to a new look at energy metabolism in bone cells, particularly 11 
osteoblasts. Quite some decades ago there had been interest in the production of lactate 12 
in the metabolism of bone, and in those days it was wondered whether the lactate might 13 
contribute an acid environment that would favour the dissolution of bone. What Fanxin 14 
Long has done is to relate increased aerobic glycolysis to anabolic events in bone – both 15 
through PTH and through Wnt signaling (21, 22). 16 
 17 
Increased metabolism of glucose through glycolysis has been recognized for a long time 18 
in cancer cells (the ‘Warburg effect’), where the intermediates of glycolysis are used by 19 
the pentose phosphate pathway to increase cell proliferation. What is shown now is that 20 
this is not the case in osteogenic cells. Using the ST2 mesenchymal cell line, it was 21 
found that Wnt3a signaling suppresses the pentose phosphate pathway, and produces 22 
energy by stimulating glutamine catabolism through the tricarboxylic acid (TCA) cycle, 23 
with the lower glutamine resulting in enhanced transcriptional activity of ATF4 and 24 
increased osteoblast differentiation. He showed that anabolic Wnts such as Wnt3a also 25 
increase aerobic glycolysis at the expense of TCA entry, resulting in a reduced 26 
availability of acetyl coenzyme A (Acetyl-CoA) associated with reduced histone 27 
acetylation, including at the PPARγ gene promoter. This mechanism in fact could 28 
provide a link between the cell’s metabolism and cell fate decisions, and explain the 29 
preferred osteoblastic (versus adipogenic) differentiation of bipotent ST2 cells in 30 
response to Wnt signalling. Consistent with these findings, LRP5-mutated knock-in 31 
mice with high bone mass (HBM) showed a partial correction of the HBM phenotype in 32 
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response to administration of either a glutaminase inhibitor (23) or a glycolysis inhibitor 1 
(21). The signaling pathways for these Wnt-LRP5 effects were noted to be mTORc1 for 2 
glutaminolysis and the anabolic effects, and mTORc2 for increasing aerobic glycolysis.  3 
 4 
Of much interest is that the glycolysis pathway is used to similar effect with PTH. PTH 5 
increases glycolysis in osteoblasts, doing so through the mediation of IGF1 signaling. 6 
Notably, suppression of glycolysis inhibited the anabolic effect of PTH in mice (22).  7 
Overexpression of the key transcription factor that orchestrates the response of cells to 8 
low oxygen tension, the hypoxia-inducible factor (HIF)-1α, was also found to exert an 9 
anabolic effect on bone. Intriguingly, the increased bone mass in these mice expressing 10 
a stable form of HIF-1α appeared to be independent of VEGF but dependent upon 11 
increased glycolysis, as administration of the glycolysis inhibitor dichloroacetate (DCA) 12 
could reverse the phenotype (24). Moreover, the physiological importance of glycolysis 13 
in osteoblast lineage cells was supported by new data showing that conditional 14 
inactivation of lactate dehydrogenase A (LDHA), the enzyme that catalyzes the inter-15 
conversion between pyruvate and lactate, results in reduced bone formation and bone 16 
mass. 17 
The attention being drawn now to these biochemical pathways offers new approaches to 18 
the understanding of osteoblast function and bone formation, particularly with regard to 19 
oxygenation of tissue, where it has been known for some time that reduction of 20 
oxygenation leads to increased glycolysis.  21 
 22 
Several short talks in this area of research explored the cellular and patho-physiological 23 
consequences of altered signaling through hypoxia-inducible pathways. Naomi Dirckx 24 
(Leuven) showed that stimulation of HIF-activity in bone cells of genetically modified 25 
mice led to excessive glycolysis in osteoblast lineage cells, associated with a dramatic, 26 
progressive increase in bone volume and, intriguingly, with systemic alterations, 27 
particularly severely affecting their whole-body glucose metabolism. In the presentation 28 
of Claire-Sophie Devignes (Paris) we learned that changes in the local bone 29 
microenvironment elicited by excessive HIF activity, through deletion of the tumor 30 
suppressor and negative regulator of HIF activity Von Hippel Lindau (Vhl), could 31 
promote breast cancer growth and lead to an increased susceptibility of mice to develop 32 
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metastatic lesions. The mechanism underlying this effect was found to involve 1 
enhanced expression of CXCL12 in the bone and bone marrow environment, acting 2 
systemically to stimulate the growth of primary mammary tumor cells (expressing the 3 
CXCR4 receptor of CXCL12/SDF-1) and their metastatic dissemination to distant 4 
organs. The roles of HIF signaling in osteoclasts were investigated by Helen Knowles 5 
(Oxford), by using in vitro osteoclastogenesis assays and mice lacking either of the key 6 
oxygen sensing enzymes upstream of HIF, termed prolyl hydroxylases (PHDs). She 7 
concluded that HIF-1a mainly affects osteoclast-mediated bone resorptive activity, 8 
while having less pronounced effects on osteoclast differentiation.  9 
 10 
 11 
The Wnt- LPR5 Signaling Pathway in Bone  12 
 13 
Of course the effects of Wnt signaling on bone, first noted only a little over ten years 14 
ago, are so marked that they always have to remain a subject of interest. We were given 15 
further insights into this by Matthew Warman (Harvard Medical School, Boston, 16 
USA), whose approach to this pathway comes through both human and mouse genetics. 17 
An important lesson is that although mouse genetics can be useful in many ways, it is 18 
safer to think of its effects in parallel with what is known about human genetic mutation 19 
effects on the skeleton. 20 
 21 
Matthew Warman pointed to the fact that a careful analysis of the expression of mRNAs 22 
for many Wnts in bone marrow, muscle and bone showed their relative expression 23 
levels. In bone the most abundantly expressed was Wnt10b, with in decreasing order 24 
Wnt4, Wnt16, Wnt5b, Wnt5a and then others (25). Overexpression of Wnt10b or its 25 
knockout gave results that might have been predicted, with the former mice having 26 
increased bone and the latter decreased. On the other hand, human mutations of Wnt10b 27 
resulted in only split hand and split foot syndromes, suggesting quite significant 28 
differences in importance between mouse and human. Of considerable interest is the 29 
fact that although Wnt1 showed a very low expression in mouse bone, human loss of 30 
function of Wnt1 results in a brittle bone disease, and in mice in which Wnt1 is knocked 31 
out, there is a decrease in both trabecular and cortical bone (26). 32 
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A mouse genetic experiment was described that illustrates a proof-of-concept that could 1 
be useful in human therapeutics. Mice with genetically induced HBM (by carrying the 2 
LRP5 HBM point mutation (27)) were crossed with osteogenesis imperfecta (OI) mice, 3 
with the result that enhanced LRP5 signaling increased the amount of bone in each of a 4 
few OI models, resulting in increased bone mass, skeletal strength and fracture 5 
resistance (28). While this is certainly promising, the question was asked why making 6 
more bone improves the outcome in OI models, even though the collagen abnormality 7 
remains? The thought was offered that perhaps this was the result of increased amount 8 
of collagen per unit of matrix. 9 
 10 
Other insights into skeletal abnormalities from genetic studies  11 
 12 
The power of genetic approaches in mice and other animal systems for getting increased 13 
insights in human pathologies and developing potential therapeutic advances was also 14 
evident from many posters and short orals throughout the meeting. For example, 15 
Antonio Maurizi (L’Aquila) presented promising results in mice on the use of highly 16 
specific, mutation-targeting small interfering RNAs as a novel experimental therapy for 17 
chloride channel type 7 (CLCN7)-dependent autosomal dominant osteopetrosis type 2 18 
(ADO2), a human disease caused by heterozygous dominant negative mutations in the 19 
CCL7 gene that lead to osteoclast dysfunction. In the same research group, Mattia 20 
Capulli (L’Aquila) closely studied the behavior and brain of the ADO2 mice, finding 21 
that the CCL7 mutation was associated with changes in the central nervous system 22 
(CNS). These important observations call for an increased awareness and evaluation of 23 
potential CNS involvement and neurological complications in ADO2 patients. In the 24 
presentation by Charlotte Gistelinck (Ghent) we were taken into the clinically relevant 25 
experimental possibilities beyond mice. She developed a zebrafish model to study the 26 
pathogenetic mechanisms leading to Bruck syndrome, a disorder reminiscent of OI and 27 
characterized by fractures. One of the causative genes is PLOD2, encoding a lysyl 28 
hydroxylase (LH2) that acts upon type I collagen telopeptides and thereby affects the 29 
stability and strength of the collagen fibrils. Here, a nonsense mutation in PLOD2 was 30 
introduced in zebrafish, resulting in musculoskeletal abnormalities and a disturbed 31 
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collagen organization in bone, underscoring the significance of this model to study 1 
Bruck syndrome.  2 
 3 
 4 
Cancer-Induced Bone Disease 5 
 6 
Claire Edwards (University of Oxford, Oxford, UK) undertook the task of discussing 7 
how tumor cells interact with the bone microenvironment, beginning by pointing out 8 
that in the case of solid tumors, these may be predominantly osteoclastic, osteoblastic, 9 
or mixed in nature. Whichever is the case, interactions between the tumor cells and the 10 
microenvironment of bone are of the utmost importance. That environment is now 11 
recognized to consist not only of osteoblasts and osteoclasts, but also stromal cells, 12 
adipocytes and lymphocytes (29). 13 
 14 
The earliest work on establishment of tumors in bone took place with solid tumors, 15 
particularly breast cancer, where the role of the osteoclast was thought to be dominant. 16 
In that case the tumors were shown to produce factors which were capable of promoting 17 
osteoclast formation by acting upon the host osteoblasts to generate the osteoclastogenic 18 
signal RANKL. The responsible tumor products were thought to be PTHrP and certain 19 
other cytokines, such as IL-11. It is increasingly realized that cellular components of the 20 
bone are important in both establishment of tumor in bone and its growth and 21 
advancement. 22 
 23 
The condition of multiple myeloma (MM) was discussed in some detail, with a major 24 
question being: how do changes in the bone microenvironment favour MM 25 
establishment and progression? MM is a major cause of blood cancer deaths in many 26 
countries, and recent data indicate that it is consistently preceded by its precursor 27 
condition, monoclonal gammopathy of unknown significance (MGUS). Although 28 
MGUS can clearly be recognized, not all patients with MGUS will progress to MM – 29 
over a period of 20 years about 16% will do so. MM is a condition which profoundly 30 
affects the skeleton. It does so by causing multiple lytic lesions in the skeleton, but also 31 
by causing a generalized bone loss which is recognized as a cause of “secondary” 32 
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osteoporosis. It is important to note also that there is clear evidence of bone loss in 1 
MGUS (30). 2 
 3 
Much useful information has come from the use of a mouse model of MM, known as 4 
the 5T myeloma model, in which 100% of the mice develop MM, with bone disease and 5 
paraprotein evident. These MM cells need to be grown and propagated in a sub-strain of 6 
C57Bl6 mice, known as KaLwRij mice. Interestingly, while 5T cells alone do not 7 
induce MM in C57Bl6 mice, co-injection of bone marrow stromal cells from KaLwRij 8 
mice together with the MM cells did lead C57Bl6 mice to grow this tumor and develop 9 
MM (31). This effect was found to be dependent on the Wnt inhibitor Dkk1, which is 10 
increased in MGUS. This important observation illustrates how the bone marrow 11 
environment can profoundly influence MM development and consequently, how 12 
pharmacologically manipulating the tumour's interactions with this niche is a major 13 
driving force in current myeloma research (32).  14 
 15 
As a next step, micro-array analysis comparing the bone marrow of non-permissive 16 
C57Bl6 mice and permissive KaLwRij mice was performed, indicating that the latter 17 
had decreased levels of adiponectin. The possibility was examined that a decrease of 18 
adiponectin in a host might increase MM progression. In support of this, increased 19 
burden of MM was found when the cells were injected into adiponectin null mice, and 20 
the conclusion from these and other experiments was that increasing adiponectin 21 
pharmacologically reduces MM growth and advance (33). Adiponectin is inversely 22 
related to obesity, and diet-induced obesity in KaLwRij mice promoted the growth of 23 
MM and its advance in bone with development of lytic lesions (34). A clinical 24 
observation relevant to this is that obesity has been found to be associated with 25 
increased MGUS (35). 26 
 27 
The links between tumor growth and the cellular components of bone are such that a 28 
number of specific pathways are being identified that either enhance or oppose tumor 29 
growth, so the area is one that merits increasing attention in bone biology research. A 30 
variety of related questions was addressed in short presentations at the workshop. Hanna 31 
Taipaleenmaki (Hamburg) investigated a microRNA (miR-218) that they had 32 
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previously shown to be highly expressed in osteoblasts and to promote osteogenic 1 
differentiation. It was found to be highly expressed also in bone-metastasizing breast 2 
cancer cells, MDA-MB231. When miR-218 was delivered to the breast cancer cells, it 3 
promoted tumor growth in bone with increased osteoclast activity and bone resorption, 4 
whereas antagonising miR–218 prevented the development of osteolytic lesions. An 5 
inhibitory effect of Wnt5a has been reported, and Stefanie Thiele (Dresden) investigated 6 
the mechanism in three human prostate cancer cell lines, showing that Frizzled 5 and 7 
RYK mediate the anti-proliferative and pro-apoptotic effects of Wnt5a in prostate 8 
cancer cells. In two short presentations, tumor-derived exosomes were found to enhance 9 
osteoclast formation. Muhammad Zahoor (Trondheim) found this in MM cells where 10 
the responsible agent was Il-32 in exosomes. Irene Bijnsdorp (Amsterdam) found that 11 
exosomes from three human prostate cancer cell lines were taken up by monocytes in 12 
vitro, thereby enhancing osteoclast formation in response to RANKL stimulation. Such 13 
mechanisms influenced by cancer-derived exosomes clearly are worth exploring further.  14 
 15 
Although the emphasis was on the tumor invasion by bone in these presentations, as is 16 
usually the case, it was interesting to have work presented concerning the major primary 17 
tumor of bone, osteosarcoma. Agi Grigoriadis (London) presented results with the c-fos 18 
oncogene-induced osteosarcoma in the mouse that results in a highly malignant, 19 
metastatic tumour that expresses high levels of Fgfr1 mRNA and FGFR1 protein, 20 
associated with sustained activation of MAPKs and increased anchorage-independent 21 
growth in response to FGF2. Orthotopic injection of osteosarcoma with knockdown of 22 
FGFR1 resulted in a marked decrease in lung metastases, and a similar effect was 23 
obtained in vivo with the administration of a small molecule inhibitor, AZD457. The 24 
prospect of using antiFGR therapies was therefore raised. 25 
 26 
 27 
Concluding remarks 28 
 29 
In the above not every presentation is mentioned, the range of topics was large and also 30 
included stem cell biology, imaging techniques for bone and insights into pathologies 31 
that are less frequently discussed, such as osteophytes and periodontal disease. There 32 
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was robust discussion after every presentation, which continued during the excellent 1 
lunches organized by our hosts in the Novotel Brugge. Overall, the meeting allowed 2 
participants to find new collaborators, learn from the invited mentors and from each 3 
other, get feedback on their work and generally network. The meeting was 4 
complemented by a social programme including a wonderful evening with dinner in the 5 
Brewery “De Halve Maan”, where we were welcomed by a glass (or more) of “de 6 
Brugse Zot”, their trademark beer. We were also very warmly welcomed in the 7 
impressive City Hall of Brugge where the chief of protocol introduced us on the long 8 
history of Brugge and especially the important role of the medieval city hall for the 9 
protection of the city rights of “het Brugse vrije” (fee state of Brugge). He also 10 
emphasized that the city now attracts more than 5 million visitors per year and invited 11 
all participants to take time to enjoy the richness of the diversity of cultural and culinary 12 
aspects of the city. Needless to say that this was followed by a reception in the historic 13 
building.  14 
On the final day a short guided tour of the city was a fitting finale to this meeting. 15 
Undeterred by the rain many participants joined our two knowledgeable local guides 16 
who took us to key sites, such as the Begijnhof, the Belfry and the Church of our Lady, 17 
where we saw the statue “the Madonna of Bruges” created by Michelangelo.  18 
 19 
 20 
The survey at the end of the meeting was completed by 80+ % of the 21 
participants and they scored the science of the meeting as excellent (68%) or 22 
good (29%), whereas 99% “loved or liked” the city of Brugge. The meeting was 23 
attended by about 100 persons coming from around the world (see Figures 1 and 24 
2). The broad international attendance was enormously facilitated by the 25 
generous support of sponsors (see acknowledgments). In addition, apart from 26 
IBMS itself, the American Society of Bone and Mineral Research (ASBMR), 27 
the European Calcified Tissue Society (ECTS), the Japanese Society for Bone 28 
and Mineral Research (JSBMR), the Australian and New Zealand Bone and 29 
Mineral Society (ANZBMR) and the Belgian Bone Club all provided travel 30 
grants, resulting in an impressive 36 travel awards in total, and such that, 31 
  
16 
16 
effectively, this last IBMS meeting already functioned as one organized by the 1 
International Federation of Musculoskeletal Research Societies (IFMRS). 2 
 3 
What next? 4 
IBMS was the organizer of the last meeting in Davos (2009) and of two H Fleisch 5 
workshops in Brugge (2014 and 2016). However IBMS has in 2016 been merged, 6 
together with ECTS, ASBMR, ANZBMS, JSBMR, SIBOMM, ORS and ICMRS, into 7 
the IFMRS. The IFMRS purpose is to advance musculoskeletal research globally in 8 
order to prevent and treat musculoskeletal diseases by collaborating with international 9 
societies to share resources, raise public awareness and provide education. The 10 
organizers of the meeting as well as most of the attendees hope that the strengthened 11 
global society will maintain the spirit of the Davos/Brugge meetings and, while learning 12 
from experience, will continue to provide a forum for young bone scientists to attend a 13 
meeting that fulfills their needs for active interaction with their young colleagues and 14 
learn from the rich experience of a few international leaders in this field. 15 
 16 
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